Physician profile
Veslav Stecevic
NPI 1659361806
$4,271.27
in general payments reported to CMS, 2019-2025
25 companies · $1,862 in 2025
The $1,862 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.22 · 2021: $31.87 · 2022: $137 · 2023: $809 · 2024: $1,418 · 2025: $1,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,993 · Education: $96.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,992.87 |
| Education | $96.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,183.66 | 2022-2025 | Rinvoq, Skyrizi, Creon |
| Takeda Pharmaceuticals U.S.A., INC. | $689.68 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $566.14 | 2023-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $190.62 | 2023-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $188.72 | 2025 | Tremfya |
| Madrigal Pharmaceuticals | $185.89 | 2024-2025 | Rezdiffra |
| Qol Medical, LLC | $168.18 | 2022-2025 | Sucraid |
| Pfizer INC. | $138.69 | 2023-2025 | |
| Ardelyx, INC. | $124.77 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $115.73 | 2023-2024 | |
| Aimmune Therapeutics, INC. | $95.06 | 2024-2025 | Vowst, Zenpep |
| Lilly USA, LLC | $94.39 | 2024-2025 | Omvoh |
| Celgene Corporation | $94.19 | 2023 | Zeposia |
| Merck Sharp & Dohme LLC | $64.11 | 2023-2024 | Dificid |
| Organon LLC | $52.02 | 2023-2024 | Hadlima, Renflexis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $51.98 | 2025 | |
| Ironwood Pharmaceuticals, INC | $45.94 | 2021-2023 | Linzess |
| Phathom Pharmaceuticals, INC. | $44.92 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.13 | 2023-2025 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $32.58 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $25.30 | 2024 | |
| Daiichi Sankyo INC. | $22.45 | 2022 | |
| Convatec INC. | $20.28 | 2024 | |
| Lucid Diagnostics INC. | $18.64 | 2024 | |
| Medtronic, INC. | $17.20 | 2025 | Interstim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veslav Stecevic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.